Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries.

Autor: Linde L; Rigshospitalet, Glostrup, Denmark., Georgiadis S; Rigshospitalet, Glostrup, Denmark., Ørnbjerg LM; Rigshospitalet, Glostrup, Denmark., Rasmussen SH; Rigshospitalet, Glostrup, Denmark., Michelsen B; Rigshospitalet, Glostrup, Denmark, Diakonhjemmet Hospital, Oslo, Norway, and Sørlandet Sykehus HF, Kristiansand, Norway., Askling J; Karolinksa Institutet, Stockholm, Sweden., Di Giuseppe D; Karolinksa Institutet, Stockholm, Sweden., Wallman JK; Skåne University Hospital, Lund, Sweden., Závada J; Institute of Rheumatology and Charles University First Faculty of Medicine, Prague, the Czech Republic., Pavelka K; Institute of Rheumatology and Charles University First Faculty of Medicine, Prague, the Czech Republic., Bernardes M; University of Porto and Centro Hospitalar Universitário de São João, Porto, Portugal., Matos CO; Hospital de Santa Maria and Centro Academico de Medicina de Lisboa, Lisbon, Portugal., Glintborg B; The DANBIO Registry, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark., Loft AG; Aarhus University Hospital and Aarhus Universitet, Aarhus, Denmark., Nordström D; Helsinki University Central Hospital, Helsinki, Finland., Kuusalo L; University of Turku and Turku University Hospital, Turku, Finland., Möller B; Inselspital University Hospital Bern, Bern, Switzerland., Nissen MJ; Geneva University Hospitals, Geneva, Switzerland., Codreanu C; University of Medicine and Pharmacy Carol Davila, Bucharest, Romania., Mogosan C; University of Medicine and Pharmacy Carol Davila, Bucharest, Romania., Gudbjornsson B; Landspitali National University Hospital of Iceland and University of Iceland, Reykjavik, Iceland., Love TJ; Landspitali National University Hospital of Iceland and University of Iceland, Reykjavik, Iceland., Akleylek C; TC Demiroglu Bilim University, Istanbul, Turkey., Iannone F; University of Bari, Bari, Italy., Kvien TK; Diakonhjemmet Hospital, Oslo, Norway., Rotar Z; University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia., Castrejon I; General University Hospital Gregorio Maranon and Complutense University of Madrid, Madrid, Spain., Macfarlane GJ; University of Aberdeen, Aberdeen, Scotland., Hetland ML; Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark., Østergaard M; Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Arthritis care & research [Arthritis Care Res (Hoboken)] 2024 Nov; Vol. 76 (11), pp. 1558-1565. Date of Electronic Publication: 2024 Aug 19.
DOI: 10.1002/acr.25396
Abstrakt: Objective: Because 66/68 joint counts are not always performed in routine care, we aimed to determine which of the modified 28-joint disease activity index for psoriatic arthritis (DAPSA28) or 28-joint disease activity score with C-reactive protein (DAS28-CRP) should be preferred for monitoring disease activity in psoriatic arthritis (PsA) when the original DAPSA (66/68 joints) is not available.
Methods: Prospectively collected real-world data of European bionaive patients with PsA initiating a first tumor necrosis factor inhibitor were pooled. Remission and response status were evaluated at 6 months by remission (DAPSA ≤ 4, DAPSA28 ≤ 4, and DAS28-CRP < 2.6), response (75% improvement for DAPSA and DAPSA28), and combined EULAR good/moderate responses for DAS28-CRP. Logistic regression analyses on multiple imputed data were used to identify baseline predictors.
Results: Remission and response cohorts included 3,159 and 1,866 patients, respectively. The 6-month proportions achieving remission/response were DAPSA (27%/44%), DAPSA28 (28%/44%), and DAS28-CRP (59%/80%). Of 14 possible baseline predictors, 11 predicted both DAPSA and DAPSA28 remission (8 of which also predicted their response, indicated by "*"): longer disease duration*, male sex*, and higher CRP* were positive, whereas older age*, higher body mass index*, patient fatigue*, and global, physician global, health assessment questionnaire score*, and tender and swollen* joint counts were negative predictors. Eight and five of these predicted DAS28-CRP remission and response, respectively.
Conclusion: In patients with PsA, DAPSA28 should be preferred over DAS28-CRP as a substitute for DAPSA when 66/68 joint counts are not available because of the large overlap in remission and response status and in predictors between DAPSA and DAPSA28.
(© 2024 The Author(s). Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
Databáze: MEDLINE
Externí odkaz: